Verification evidence is still being completed.
PDF / print export
Cantargia
Lund, Sweden
- Verified lead
- Damian Marron
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Antibody Therapeutics, Oncology, Inflammation, and Clinical Drug Development
- Review cycle
- May 2026
- Full address
- Sankt Annegatan 1, 223 50 Lund, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Cantargia company material confirming the Sankt Annegatan 1 Lund address.
- Editorial note
- Cantargia is published because official company materials confirm current leadership, Lund operating address, and a strong antibody-based therapeutics platform.
Antibody Therapeutics, Oncology, Inflammation, and Clinical Drug Development
Official leadership disclosure, Official Lund address disclosure, Clinical therapeutics platform claim
Cantargia is published because official company materials confirm current leadership, Lund operating address, and a strong antibody-based therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lund, Sweden
Cantargia
Antibody Therapeutics, Oncology, Inflammation, and Clinical Drug Development · Clinical-stage therapeutics platform
Cantargia runs antibody drug development, oncology programs, and inflammation therapeutics in Lund, Sweden.
- Lead
- Damian Marron (verified ↗)
- Address
- Sankt Annegatan 1, 223 50 Lund, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Antibody Drug Development · Oncology Programs · Inflammation Therapeutics
- Founded
- 2009
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Damian Marron
CEO
Full addressSankt Annegatan 1, 223 50 Lund, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Cantargia company material listing the Sankt Annegatan 1 Lund address.
Open sourceClinical-stage therapeutics platform
Lund, Sweden. Antibody Therapeutics, Oncology, Inflammation, and Clinical Drug Development. Review completed on 21 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Lund address disclosure, Clinical therapeutics platform claim
Antibody Therapeutics, Oncology, Inflammation, and Clinical Drug Development
Cantargia is published because official company materials confirm current leadership, Lund operating address, and a strong antibody-based therapeutics platform.
Editorial note
Cantargia is published because official company materials confirm current leadership, Lund operating address, and a strong antibody-based therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Antibody Drug Development
Oncology Programs
Inflammation Therapeutics
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Antibody-development workflow
Clinical program infrastructure
Therapeutics R&D systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Cantargia located?
- Cantargia operates from Sankt Annegatan 1, 223 50 Lund, Sweden, Lund, Sweden.
- Who runs Cantargia?
- Cantargia is led by Damian Marron, CEO. Verified 21 Mar 2026.
- What does Cantargia do?
- Cantargia runs antibody drug development, oncology programs, and inflammation therapeutics in Lund, Sweden. Core capabilities: Antibody Drug Development, Oncology Programs, Inflammation Therapeutics.
Editorial context
Related technical briefs
Briefs that name Lund as a covered market or city.